Developing drugs to prevent hearing loss caused by certain antibiotics
Therapeutics to prevent aminoglycoside-induced hearing loss
['FUNDING_SBIR_2'] · TING THERAPEUTICS, INC. · NIH-11228816
This study is looking at a new medicine called TT003, made from a natural pepper, to see if it can help protect your hearing while you take certain antibiotics that can sometimes cause hearing loss, and if it works well, it could be a great option for people needing these antibiotics.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | TING THERAPEUTICS, INC. (nih funded) |
| Locations | 1 site (San Diego, UNITED STATES) |
| Trial ID | NIH-11228816 on ClinicalTrials.gov |
What this research studies
This research focuses on creating new medications to protect against hearing loss that can occur from the use of aminoglycoside antibiotics, which are commonly prescribed for serious bacterial infections. The team is investigating a compound called TT003, derived from a natural pepper, which has shown promise in animal models for reducing hearing loss associated with these antibiotics. The research involves testing the effectiveness of TT003 in various dosing regimens and understanding how it interacts with the antibiotics to ensure both efficacy in fighting infections and protection against hearing loss. Patients may benefit from this research if the drug proves effective in clinical trials.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who are prescribed aminoglycoside antibiotics and are at risk of developing hearing loss.
Not a fit: Patients who are not receiving aminoglycoside antibiotics or those with pre-existing hearing loss unrelated to antibiotic use may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a medication that prevents hearing loss in patients receiving aminoglycoside antibiotics.
How similar studies have performed: While there have been various approaches to prevent hearing loss from aminoglycosides, the specific use of TT003 is a novel approach that has not yet been widely tested in clinical settings.
Where this research is happening
San Diego, UNITED STATES
- TING THERAPEUTICS, INC. — San Diego, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ZUO, JIAN — TING THERAPEUTICS, INC.
- Study coordinator: ZUO, JIAN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.